



HAL
open science

Isolated 5' Signals Are an Atypical Pattern To Be Considered as Positive for ALK Rearrangement: A Brief Report of Three Cases and Review of the Literature

Alice Guyard, Cécile Charpy, Nathalie Théou-Anton, Anne Cremades, Frédéric Grassin, Anaïs Bourgogne, Karen Leroy, Anaïs Pujals, Christiane Copie-Bergman, Christos Chouaid, et al.

► To cite this version:

Alice Guyard, Cécile Charpy, Nathalie Théou-Anton, Anne Cremades, Frédéric Grassin, et al.. Isolated 5' Signals Are an Atypical Pattern To Be Considered as Positive for ALK Rearrangement: A Brief Report of Three Cases and Review of the Literature. *Translational Oncology*, 2019, 12 (5), pp.784 - 787. 10.1016/j.tranon.2019.02.015 . hal-04145745

HAL Id: hal-04145745

<https://hal.u-pec.fr/hal-04145745v1>

Submitted on 29 Jun 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Isolated 5' Signals Are an Atypical Pattern To Be Considered as Positive for ALK Rearrangement: A Brief Report of Three Cases and Review of the Literature¹



Alice Guyard^{*}, Cécile Charpy[†],
Nathalie Théou-Anton[‡], Anne Cremades[§],
Frédéric Grassin[¶], Anaïs Bourgoigne[#],
Karen Leroy^{**}, Anaïs Pujals[†], Christiane Copie-
Bergman[†], Christos Chouaid^{††2} and
Audrey Mansuet-Lupo^{*2}

^{*} Department of Pathology, HUPC, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris 75014, France; [†] Department of Pathology, Hôpital Henri Mondor, Assistance Publique-Hôpitaux de Paris, 94010, Créteil, France; [‡] Department of Genetic, Hôpital Bichat-Claude Bernard, Assistance Publique-Hôpitaux de Paris, 75877, Paris, France; [§] Department of Pathology, Hôpital Bégin, 94160, Saint Mandé, France; [¶] Department of Pneumology, Hôpital Percy, 92190, Clamart, France; [#] Department of Pathology, Centre Intercommunal de Créteil, 94000 Créteil, France; ^{**} Department of Genetic and Molecular Biology, HUPC, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris 75014, France; ^{††} Department of Pneumology, Centre Intercommunal de Créteil, 94000 Créteil, France

Abstract

Anaplastic lymphoma kinase (*ALK*) rearrangement is reported in 3% to 8% of patients with lung adenocarcinoma and can be detected by fluorescent *in situ* hybridization (FISH) or indirectly by immunohistochemistry. In FISH assay, isolated 5' signal (loss of 3' signal) is usually considered negative. We report three young nonsmoking patients with stage IV lung adenocarcinoma. Strong *ALK* expression in tumor cells detected by immunohistochemistry was observed in all cases, but FISH revealed an isolated 5' signal pattern. Massive parallel “next-generation” sequencing was performed in two patients and confirmed *ALK* rearrangement. The three patients were treated and responded to crizotinib after 14, 10, and 31 months.

Translational Oncology (2019) 12, 784–787

Introduction

Anaplastic lymphoma kinase (*ALK*) rearrangements are reported in 3% to 8% of patients with lung adenocarcinoma [1,2]. *ALK* rearranged adenocarcinomas often occur in young and nonsmoker patients, with advanced-stage disease and lymph node metastases [3]. Tumors with *ALK* gene rearrangement have a rapid and pronounced response to the *ALK* tyrosine kinase inhibitor. Thus, identification of this driver gene alteration is mandatory in routine diagnosis because approved molecular targeted drugs are available [4]. Currently, the most widely established accurate method for identifying *ALK* rearrangements is fluorescent *in situ* hybridization (FISH) with an *ALK* break-apart probe, but immunohistochemistry (IHC) has been validated as an equivalent alternative to FISH for *ALK* testing according to the newly revised College of American Pathologists/International Association for the Study of Lung Cancer/Association

for Molecular Pathology (CAP/IASLC/AMP) guidelines [5]. The FISH criterion for categorizing lung tumors as *ALK* positive are $\geq 15\%$ of tumor cells showing a positive signal pattern that includes split signals (at least

Address all correspondence to: Audrey Mansuet-Lupo, Department of pathology, HUPC, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, 27 rue faubourg Saint Jacques, 75014 Paris, France. E-mail: audrey.lupo@aphp.fr

¹ This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

² Audrey Mansuet-Lupo and Christos Chouaid equally contributed to this study. Received 5 January 2019; Revised 21 February 2019; Accepted 21 February 2019

© 2019 The Authors. Published by Elsevier Inc. on behalf of Neoplasia Press, Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1936-5233/19

<https://doi.org/10.1016/j.tranon.2019.02.015>

two signal distances apart) and/or an isolated 3' signal. Although these two patterns are the most common, other patterns can be observed. Loss of 5' signal with amplification of 3' signal is also considered positive for *ALK* rearrangement. In contrast, loss of 3' signal (isolated 5' signal) is usually considered negative [6–8]. We report here three cases with an isolated 5' signal pattern by FISH confirmed for two of them as *ALK* rearrangement by massive parallel “next-generation” sequencing (NGS). All of these three patients had still complete response under crizotinib 14, 10, and 31 months after the diagnosis.

Case Summary

Case 1

A nonsmoking 46-year-old woman presented with anterior chest pain of several months' duration and asthenia. The patient had no medical history except for an antiphospholipid antibody syndrome. A computed tomography (CT) scan showed a pleural thickening developed on parietal and fissural pleura, without pleural effusion. The CT scan, completed with a positron emission tomography/CT scan, showed neither parenchymal lesion nor lymphadenopathy. Videothoracoscopy revealed a nodular thickened pleura. Microscopically, the pleura was massively infiltrated by an adenocarcinoma of solid, acinar, and cribriform pattern (Figure 1A). In IHC, tumor cells were positive for TTF1 (SPT24, Tebu-Novocastra) and *ALK* (5A4, Abcam) (Figure 1B), and negative for P40 (BC28, Zytomed). Break-apart FISH (Zytovision) showed isolated 5' *ALK* signals with loss of 3' *ALK* signals in 60% of tumoral cells, split signals in 10% of




Figure 1. Case 1: (A) Adenocarcinoma with solid, acinar, and cribriform pattern (HES) $\times 40$. (B) Strong positivity (3+) of *ALK* immunohistochemistry (5A4, Abcam). (C) Isolated 5' *ALK* signals and rare split signals (Zytovision break-apart *ALK* FISH). Case 2: (D) Adenocarcinoma of solid pattern with signet ring cells (HES) $\times 40$. (E) Strong positivity (3+) of *ALK* immunohistochemistry (5A4, Abcam). (F) Isolated 5' *ALK* signals with two normal fusion signal per cell (DAKO break-apart *ALK* FISH). Case 3: (G) Adenocarcinoma with solid and cribriform pattern (HES) $\times 20$. (H) Strong positivity (3+) of *ALK* immunohistochemistry (5A4, Abcam). (I) Isolated 5' *ALK* signals (DAKO break-apart *ALK* FISH).

tumoral cells, and normal fused signals in 30% of tumoral cells (Figure 1C). The presence of an *EML4* (ex6)–*ALK* (ex20) transcript was confirmed by NGS (OncoPrint solid tumor fusion transcript kit, Life Technology). DNA analyses by an NGS 22-gene panel showed no additional mutation (OncoPrint solid tumor DNA kit, Life Technologies). The patient received a first-line crizotinib and is in complete response 14 months after the diagnosis.

Case 2

A nonsmoking 45-year-old woman presented with right pleural effusion. A CT scan showed two bilateral pulmonary nodules and several localizations in left adrenal gland and brain. A biopsy of a pulmonary nodule revealed an adenocarcinoma of solid, acinar, and cribriform pattern with a minor mucinous component (Figure 1D). In IHC, tumor cells were positive for TTF1 (SP141, Roche) and ALK (5A4, ByoSystems) (Figure 1E), and negative for P40 (BC28, Roche). Break-apart FISH (DAKO) showed several (3 to 4) very small isolated 5' *ALK* signals with loss of 3' *ALK* signals in 61% of tumoral cells, associated with split signals in 4% of tumoral cells and fused signals in 35% of tumoral cells (Figure 1F). The presence of an *EML4* (ex13)–*ALK* (ex20) transcript was confirmed by NGS (OncoPrint solid tumor fusion transcript kit, Life Technologies). DNA analyses by an NGS 22-gene panel show no additional mutation (OncoPrint solid tumor DNA kit, Life Technologies). The patient was treated with crizotinib, which led to a complete regression of pulmonary nodules, right pleural effusion, and adrenal gland and cerebral lesions. The patient is still under crizotinib 10 months after the diagnosis.

Case 3

A nonsmoking 40-year-old man, with no personal history, presented with dyspnea. A CT scan showed a bulky mediastinal mass behind the left main bronchus classified cT4N2M0. The biopsy, made by endobronchial ultrasound-guided transbronchial needle aspiration, showed an adenocarcinoma of cribriform pattern (Figure 1G). In IHC, tumor cells were positive for TTF1 (8G7G3/1, Roche) and ALK (5A4, Clinisciences) (Figure 1H). Break-apart FISH (DAKO) showed two to three 5' *ALK* signals with loss of 3' *ALK* signals in 87% of tumoral cells and fused signals in 13% of tumoral cells (Figure 1I). DNA analysis showed no mutation on *EGFR* (HRM PCR screening; fragment analysis, Genescan; Taqman probe; Entrogen kit), *KRAS* (HRM PCR screening), *BRAF* (HRM PCR screening), and *ERBB2* (HRM PCR screening) genes. Confirmation by RNA NGS could not be performed as tumoral sample was not sufficient for analysis. The evaluation at 6 weeks after the beginning of crizotinib showed a complete response still ongoing 31 months after the diagnosis.

Discussion

To date, FISH is the standard procedure for the detection of *ALK* rearrangement in non-small cell lung carcinoma (NSCLC). Commonly, *ALK* break-apart probes were used, including a DNA fragment telomeric to *ALK* (3' end) labeled with red fluorophore and a DNA fragment centromeric to *ALK* (5' end) labeled green fluorophore. Until now, rearranged *ALK* is defined by either split signal or isolated 3' signal (solitary red). Isolated 5' signal (solitary green) seems to be rare. In our two laboratories, we found only these three cases in 2 years among 367 cases tested. This pattern has usually been considered negative for rearrangement because the ALK tyrosine kinase domain is located in the 3' region of the gene [8]. In the

Table 1. Isolated 5' *ALK* Signals *ALK* FISH Pattern from Literature Reports and Our Cases

Reference	Sex, Age	ALK IHC	Partner Gene	Crizotinib Response
Yoshida [7]	NS	Positive	<i>EML4</i>	NS
Dai [8]	NS	NS	NS	NS
Dai [8]	NS	NS	NS	NS
Ren [9]	M 44 yo	Positive	<i>EML4</i>	Yes
Li [10]	F 43 yo	Positive	<i>EML4</i>	NS
Li [10]	F 45 yo	Positive	<i>BIRC6</i>	NS
Patient 1	F 46 yo	Positive	<i>EML4</i>	Yes
Patient 2	F 45 yo	Positive	<i>EML4</i>	Yes
Patient 3	M 40 yo	Positive	NS	Yes

NS, nonspecified; M, male; F, female; yo, years old.

literature, isolated 5' signal (loss of 3' *ALK* signal) has already been described in six cases (Table 1 [7–10]), and this pattern has been validated as *ALK* rearrangement at RT-PCR level in four cases [7,9,10]. Interestingly, this atypical FISH pattern was associated to the most common fusion partner, *EML4*, as in classic cases. Indeed, *EML4* was reported in three out of four cases, as in our two cases, and *BIRC6* partner was described in one case. Likewise, clinically, patients with 5' *ALK* isolated FISH signal pattern adenocarcinoma show similar clinical features as patients with classic *ALK* FISH pattern tumors: young patients, aged 40 to 46 years and nonsmokers or light smokers. Adenocarcinoma pathological features are also very similar with acinar, solid, or cribriform pattern of growth. The three patients in our series have been successfully treated with crizotinib as reported in one patient in the literature [9].

The molecular significance of the loss of the 3' signal is unclear. According to Li, this atypical FISH pattern is caused by a large deletion of the *ALK* 3' region, and the remaining region containing the *ALK* kinase domain (approximately 30 kb) is too short to be clearly observed by FISH on formalin-fixed, paraffin-embedded specimens [10]. This finding confirms the importance of the first screening by ALK immunohistochemistry as in the new recommendations [5] since immunohistochemistry was positive for all four cases described in literature and also in ours. Nevertheless, we are not aware of any reported cases with negative immunohistochemistry and with this atypical FISH pattern. Moreover, several studies have compared IHC and FISH, and they mainly indicated a high concordance to detect *ALK* rearrangement [11–13] as ALK IHC is considered as a screening method to select specimens for ALK FISH testing [4]. Thus, the newly revised CAP/IASLC/AMP guidelines published in March 2018 validated IHC as an equivalent alternative to FISH for ALK testing. Authors claim that treatment decisions can be made when IHC results are clearly positive; however, the specificity of weak staining relative to FISH should be determined in each laboratory during validation [5]. Using these guidelines, all patients of our series with this atypical *ALK* FISH pattern would have been treated by ALK inhibitor since all showed a strongly positive (3+) ALK IHC even though *ALK* FISH was considered negative. However, many institutions still perform *ALK* testing exclusively by FISH or, as in our laboratories, confirm ALK positive staining by FISH; therefore, the report of isolated 5' signals as positive pattern with efficacy of ALK TKI appeared mandatory. Alternative techniques for the detection of rearrangement, like RNA-based NGS assay, could be used to confirm these discordant cases. Scattone et al. reported seven discordant cases showing *ALK* FISH-positive cases with complex pattern of rearrangements (deleted, split, and amplified/polysomy patterns) with negative ALK IHC and inefficiency of crizotinib. NGS

assay was useful, showing lack of *ALK* fusion transcripts in these cases, which might explain the absence of the *ALK* protein [14].

In conclusion, NSCLC with positive *ALK* IHC and isolated 5' *ALK* signals pattern is a rare event that should be considered positive for *ALK* rearrangement, and patients should benefit from *ALK*-targeted therapy. This report underlines the importance of using immunohistochemistry as a prescreening method and to confirm discordant or atypical cases by alternative techniques like NGS.

Acknowledgement

We would like to thank Anne Audebourg at the Department of Pathology, Cochin Hospital, Paris, and Maryse Baia at the Department of Pathology, Mondor Hospital, Creteil, for their excellent technical support.

References

- [1] Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, and Ishikawa S, et al (2007). Identification of the transforming EML4-*ALK* fusion gene in non-small-cell lung cancer. *Nature* **448**, 561–566. <https://doi.org/10.1038/nature05945>.
- [2] Camidge DR, Kono SA, Lu X, Okuyama S, Barón AE, and Oton AB, et al (2011). Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. *J Thorac Oncol Off Publ Int Assoc Study Lung Cancer* **6**, 774–780. <https://doi.org/10.1097/JTO.0b013e31820cf053>.
- [3] Wang W, Liang D, Yao W, Wu W, Li J, and Chen M, et al (2014). Immunohistochemical screening and fluorescence in situ hybridization confirmation of *ALK* translocation in lung adenocarcinoma and its clinicopathological significance: a single-center large-scale investigation of Chinese patients. *Hum Pathol* **45**, 1414–1422. <https://doi.org/10.1016/j.humpath.2014.02.015>.
- [4] Devarakonda S, Morgensztern D, and Govindan R (2015). Genomic alterations in lung adenocarcinoma. *Lancet Oncol* **16**, e342–e351.
- [5] Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, and Bernicker EH, et al (2018). Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors; guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. *J Thorac Oncol Off Publ Int Assoc Study Lung Cancer* **13**, 323–358. <https://doi.org/10.1016/j.jtho.2017.12.001>.
- [6] Kwak EL, Bang Y-J, Camidge DR, Shaw AT, Solomon B, and Maki RG, et al (2010). Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. *N Engl J Med* **363**, 1693–1703. <https://doi.org/10.1056/NEJMoa1006448>.
- [7] Yoshida A, Tsuta K, Nitta H, Hatanaka Y, Asamura H, and Sekine I, et al (2011). Bright-field dual-color chromogenic in situ hybridization for diagnosing echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-positive lung adenocarcinomas. *J Thorac Oncol Off Publ Int Assoc Study Lung Cancer* **6**, 1677–1686. <https://doi.org/10.1097/JTO.0b013e3182286d25>.
- [8] Dai Z, Kelly JC, Meloni-Ehrig A, Slovak ML, Boles D, and Christacos NC, et al (2012). Incidence and patterns of *ALK* FISH abnormalities seen in a large unselected series of lung carcinomas. *Mol Cytogenet* **5**, 44. <https://doi.org/10.1186/1755-8166-5-44>.
- [9] Ren S, Hirsch FR, Varella-Garcia M, Aisner DL, Boyle T, and Zhou C, et al (2014). Atypical negative *ALK* break-apart FISH harboring a crizotinib-responsive *ALK* rearrangement in non-small-cell lung cancer. *J Thorac Oncol Off Publ Int Assoc Study Lung Cancer* **9**, e21–e23. <https://doi.org/10.1097/JTO.000000000000013>.
- [10] Li W, Zhang J, Guo L, Chuai S, Shan L, and Ying J (2017). Combinational analysis of FISH and immunohistochemistry reveals rare genomic events in *ALK* fusion patterns in NSCLC that responds to crizotinib treatment. *J Thorac Oncol Off Publ Int Assoc Study Lung Cancer* **12**, 94–101. <https://doi.org/10.1016/j.jtho.2016.08.145>.
- [11] Thunnissen E, Bubendorf L, Dietel M, Elmberger G, Kerr K, and Lopez-Rios F, et al (2012). EML4-*ALK* testing in non-small cell carcinomas of the lung: a review with recommendations. *Virchows Arch Int J Pathol* **461**, 245–257. <https://doi.org/10.1007/s00428-012-1281-4>.
- [12] Wynes MW, Sholl LM, Dietel M, Schuurung E, Tsao MS, and Yatabe Y, et al (2014). An international interpretation study using the *ALK* IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between *ALK* IHC and *ALK* FISH and between evaluators. *J Thorac Oncol Off Publ Int Assoc Study Lung Cancer* **9**, 631–638. <https://doi.org/10.1097/JTO.0000000000000115>.
- [13] Paik JH, Choe G, Kim H, Choe J-Y, Lee HJ, and Lee C-T, et al (2011). Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization. *J Thorac Oncol Off Publ Int Assoc Study Lung Cancer* **6**, 466–472. <https://doi.org/10.1097/JTO.0b013e31820b82e8>.
- [14] Scatone A, Catino A, Schirosi L, Caldarola L, Tommasi S, and Lacalamita R, et al (2018). Discordance between FISH, IHC, and NGS analysis of *ALK* status in advanced non-small cell lung cancer (NSCLC): a brief report of 7 cases. *Transl Oncol* **12**, 389–395. <https://doi.org/10.1016/j.tranon.2018.11.006>.